Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys

Primary aldosteronism (PA) is the most common cause of secondary hypertension but is frequently underrecognized and undertreated. Patients with PA are at a markedly increased risk for target organ damage to the heart and kidneys. While patients with unilateral PA can be treated surgically, many pati...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of medicine 2023-01, Vol.74 (1), p.217-230
Main Authors: Cohen, Jordana B, Bancos, Irina, Brown, Jenifer M, Sarathy, Harini, Turcu, Adina F, Cohen, Debbie L
Format: Article
Language:English
Subjects:
Blood Pressure
cardiovascular disease
chronic kidney disease
Diabetes mellitus
Endocrine disorders
Humans
Hyperaldosteronism - drug therapy
Hyperaldosteronism - surgery
hypertension
Hypertension - drug therapy
Kidney
Kidney diseases
mineralocorticoid receptor antagonists
Mineralocorticoid Receptor Antagonists - therapeutic use
Patients
primary aldosteronism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary aldosteronism (PA) is the most common cause of secondary hypertension but is frequently underrecognized and undertreated. Patients with PA are at a markedly increased risk for target organ damage to the heart and kidneys. While patients with unilateral PA can be treated surgically, many patients with PA are not eligible or willing to undergo surgery. Steroidal mineralocorticoid receptor antagonists (MRAs) are highly effective for treating PA and reducing the risk of target organ damage. However, steroidal MRAs are often underprescribed and can be poorly tolerated by some patients due to side effects. Nonsteroidal MRAs reduce adverse renal and cardiovascular outcomes among patients with diabetic kidney disease and are bettertolerated than steroidal MRAs. While their blood pressure-lowering effects remain unclear, these agents may have a potential role in reducing target organ damage in patients with PA.
ISSN:0066-4219
1545-326X
1545-326X
DOI:10.1146/annurev-med-042921-100438